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Introduction {#sec005}
============

Significant strides have been made in the control and treatment of malaria since the year 2000. However, there has been a rise in drug-resistant parasites and insecticide-resistant mosquitos, and progress towards elimination has stalled over recent years. Development of additional tools, including highly efficacious vaccines, would greatly aid efforts to further decrease clinical disease and mortality due to *Plasmodium falciparum*. Considering the suboptimal protection afforded by single antigen vaccines such as RTS,S \[[@pone.0232355.ref001]--[@pone.0232355.ref003]\], it is likely that induction of broad responses against multiple targets will be required to achieve adequate efficacy. While the ideal vaccine would induce sterilizing immunity, a more attainable, yet still impactful goal, may be the development of a multistage vaccine capable of reducing both the severity of clinical disease and parasite transmission rates.

One strategy being pursued for the rational development of a multivalent subunit malaria vaccine requires the production of high-quality and potent recombinant immunogens that can be successfully combined into a single formulation while adequately maintaining the protective effect of each component. These have been challenges for the field, as many protective targets are structurally complex and difficult to produce properly in recombinant form. Furthermore, antigenic competition has been observed with various formulations that incorporated multiple pre-erythrocytic and/or blood-stage antigens \[[@pone.0232355.ref004]--[@pone.0232355.ref006]\]. We developed a strategy to help facilitate this process and address the issues of vaccine production, folding and immunogenicity while minimizing antigenic competition, through the use of merozoite surface protein 8 (*Pf*MSP8) as a malaria-specific carrier protein.

Antibodies directed against conformational epitopes within the C-terminal epidermal growth factor-like domains of *P*. *falciparum* merozoite surface protein 1 (*Pf*MSP1) are highly protective in rodent and non-human primate models of malaria \[[@pone.0232355.ref007]--[@pone.0232355.ref014]\]. However, in clinical trials of *Pf*MSP1~42~, efficacy was limited due, in part, to suboptimal immunogenicity and epitope polymorphism \[[@pone.0232355.ref015]--[@pone.0232355.ref021]\]. Our early studies in the *P*. *yoelii* rodent model pointed to the potential of MSP8 as a vaccine carrier to avoid antigenic competition, to enhance the production of *Py*MSP1~19~-specific antibodies and to provide solid \[[@pone.0232355.ref022]\] and durable \[[@pone.0232355.ref023]\] protection against lethal *P*. *yoelii* malaria. Therefore, we tested the utility of this approach for *P*. *falciparum*. *Pf*MSP8 was engineered to be highly expressed, properly folded and easily purified using an *E*. *coli* expression system \[[@pone.0232355.ref024]\]. To assess the ability of *Pf*MSP8 to enhance the production, folding and immunogenicity of *Pf*MSP1~19~, a chimeric antigen containing r*Pf*MSP1~19~ genetically fused to the N-terminus *Pf*MSP8 was generated \[[@pone.0232355.ref025]\]. The resulting fusion protein, r*Pf*MSP1/8, i) was expressed and purified in high yield, bearing proper conformation of the *Pf*MSP1~19~ domain, ii) induced a predominant *Pf*MSP8-specific T cell response, iii) elicited high titers of antigen-specific antibodies in inbred and outbred mice, rabbits and non-human primates, which were cross-reactive with *Pf*MSP1~19~ from the FVO and 3D7 strains of *P*. *falciparum*, and iv) could be formulated with diverse adjuvants to stimulate production of anti-*Pf*MSP1~19~ antibodies that potently inhibited the *in vitro* growth of *P*. *falciparum* blood-stage parasites. Using a similar strategy, we have also reported success utilizing *Pf*MSP8 as a carrier for a second blood-stage target, *P*. *falciparum* merozoite surface protein 2 (*Pf*MSP2), to elicit antibodies that opsonize merozoites for phagocytosis \[[@pone.0232355.ref026]\].

*Pf*s25 is a highly conserved, 25 kDa glycosylphosphatidylinositol (GPI) anchored surface protein expressed exclusively during the sexual stages of the parasite life cycle within the mosquito midgut \[[@pone.0232355.ref027]\]. It is well established that vaccine-induced antibodies directed against conformational epitopes within the four EGF-like domains of *Pf*s25 are able to block sexual stage development within the vector, effectively preventing parasite transmission \[[@pone.0232355.ref028]--[@pone.0232355.ref032]\]. This induction of transmission-blocking immunity has been demonstrated in mouse models, non-human primates and human subjects. However, similar to *Pf*MSP1, it has been difficult to produce sufficient quantities of high quality recombinant *Pf*s25 bearing proper conformation using common expression systems. Thus far, clinical trials conducted on *Pf*s25-based candidates have resulted in suboptimal immunogenicity and durability of vaccine induced responses \[[@pone.0232355.ref033]--[@pone.0232355.ref036]\]. To begin to address these issues, we produced a chimeric r*Pf*s25-*Pf*MSP8 fusion protein as well as unfused, mature r*Pf*s25 \[[@pone.0232355.ref037]\]. r*Pf*s25 was purified with a modest yield but required denaturation and renaturation procedures to obtain the correct conformation. In contrast, r*Pf*s25/8 was purified in higher yield without the need for refolding. Both antigens were immunogenic in rabbits, inducing IgG that bound native, macrogamete-associated *Pf*s25 and exhibited potent transmission-reducing activity in a standard membrane feeding assay (SMFA).

Here, we sought to systematically assess the relative immunogenicity of these *Pf*s25-based vaccines as a function of several formulation parameters including adjuvant selection and antigen dose, with the ultimate goal of selecting an optimized *Pf*s25-based antigen for incorporation into a multivalent vaccine. We tested the influence of two distinct human-compatible adjuvants on the anti-*Pf*s25 responses. Alhydrogel (Alum), a safe and widely used adjuvant for childhood vaccines, has been shown to enhance humoral immunity and skew immune responses toward a Th~2~ profile with production of IL-5 and IgG1 antibodies \[[@pone.0232355.ref038], [@pone.0232355.ref039]\]. In contrast, GLA-SE is a two-component adjuvant that contains glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, in a stable squalene-in-water emulsion (SE). GLA-SE shifts responses toward a Th~1~ profile characterized by increased production of IFNγ and TNFα with a more diverse IgG subclass profile featuring increased levels of the cytophilic IgG2a/c in mice \[[@pone.0232355.ref040]\]. As a next step in building a multistage vaccine, the *Pf*s25/8 and *Pf*MSP1/8 vaccines were tested in combination to i) assess the potential for antigenic competition, ii) select an optimal adjuvant for the bivalent formulation, and iii) determine the impact of concurrent immunization with two subunit vaccines fused to the same carrier protein.

Materials and methods {#sec006}
=====================

Mice and immunizations {#sec007}
----------------------

Five-week-old, male CB6F1/J mice (BALB/c x C57BL/6) or male and female outbred CD1 mice were obtained from The Jackson Laboratory and Charles River Laboratories, respectively. Mice were maintained in the Animal Care Facility of Drexel College of Medicine under specific-pathogen-free conditions. All animal studies were designed, reviewed, approved and conducted in accordance with the Institutional Animal Care and Use Committee of Drexel University College of Medicine (protocol \# 20308). For comparative immunogenicity studies in CB6F1/J mice, groups (n = 5) were immunized with 0.5 μg/dose (low) or 2.5 μg/dose (high) of purified r*Pf*s25, r*Pf*s25/8, r*Pf*MSP8 or an admixture of r*Pf*s25 + r*Pf*MSP8 (0.5 μg or 2.5 μg of each antigen/dose). Production and purification of recombinant antigens have been previously reported \[[@pone.0232355.ref037]\]. Antigens were formulated in either 2% Alhydrogel adjuvant (500 μg/dose; InvivoGen, San Diego, CA) or GLA-SE (5 μg/dose, Infectious Disease Research Institute, Seattle, WA). Additional control groups received adjuvant alone. For the bivalent vaccine study, groups of CD1 mice (n = 10; 5 male and 5 female) were immunized subcutaneously with 2.5 μg/dose of purified r*Pf*s25/8, r*Pf*MSP1/8, an admixture of r*Pf*MSP1/8 + r*Pf*s25/8 (2.5 μg of each antigen/dose) or adjuvant alone. Antigens were formulated, as above, with Alum or GLA-SE as adjuvant. For assessment of antibody responses, mice were immunized subcutaneously, three times at 4-week intervals. Sera samples were collected three weeks following the first two immunizations and 4 weeks following the final immunization. For assessment of T cell responses, mice were immunized subcutaneously three times at 4-week intervals. Following an 8--10 week rest, mice received an additional boost by intraperitoneal (i.p.) injection to increase trafficking of antigen-specific T cells to the spleen. Splenocytes were harvested 2 weeks following the i.p. boost.

Antigen-specific T cell analysis {#sec008}
--------------------------------

### Splenocyte preparation {#sec009}

Harvested spleens were processed into single cell suspensions in sterile complete medium consisting of RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 2 mM L- glutamine, 0.5 mM sodium pyruvate, 50 μM 2-mercaptoethanol, 1X streptomycin/penicillin (Corning Costar Corporation, Cambridge, MA), 10 μg/ml of Polymyxin B (Sigma-Aldrich) and 10% heat-inactivated Benchmark^™^ fetal bovine serum (Gemini Bio Products, Sacramento, CA). Cellular debris was removed from suspensions by filtration through Falcon 70 μm cell strainers (Thermo Fisher Scientific). RBCs were lysed using ACK lysis buffer (Thermo Fisher Scientific), and the quantification of viable splenocytes was determined by microscopy following trypan blue staining (Thermo Fisher Scientific).

### T cell proliferation assay {#sec010}

To measure antigen-specific proliferative responses, splenocytes (5 mice/group) were plated in 96-well round-bottomed Falcon plates (Thermo Fisher Scientific) at a concentration of 2 x 10^5^ cells/well. Cells from each mouse were stimulated in triplicate in RMPI complete medium containing 10 μg/ml of r*Pf*s25, r*Pf*s25/8, or r*Pf*MSP8 antigens. Additional sets of wells from each mouse were stimulated in triplicate with Concanavalin A (Sigma-Aldrich; 1 μg/ml) or left unstimulated to serve as positive and negative controls, respectively. Plates were incubated at 37°C in 5% CO~2~ for 96 hours, and pulsed with methyl \[^3^H\]-thymidine (1 μCi/well; 70--90 Ci/mmol; PerkinElmer, Inc., Waltham, MA) for the final 18 hours. Cells were harvested onto glass fiber filters using an automatic cell harvester (PerkinElmer, Inc.). Incorporation of \[^3^H\]-thymidine was quantified by liquid scintillation counting (PerkinElmer, Inc). The stimulation indices were calculated for each animal as the mean counts per minute of each stimulated condition divided by the mean counts per minute of the corresponding unstimulated condition.

### Cytokine production {#sec011}

For the quantification of secreted cytokines induced by antigen-specific stimulation, splenocytes were plated in 96-well round-bottomed Falcon plates at a concentration of 5 x 10^5^ cells/well and stimulated as described above for 96 hours. Culture supernatants were transferred to new plates and stored at -80°C. Custom magnetic Luminex^®^ assay kits (R&D Systems, Minneapolis, MN) were used for the quantification of IL-2, IL-4, IL-5, TNFα and IFNγ in cell supernatants according to the manufacturer's protocol, utilizing a Luminex 200 analyzer and xPONENT3.1 software. Based on a standard curve, concentrations (pg/ml) of each analyte were calculated for all samples and final, antigen-specific concentrations were determined by subtracting out the background levels in corresponding unstimulated conditions.

Determination of antigen-specific antibody titers {#sec012}
-------------------------------------------------

### Enzyme-linked immunosorbent assay (ELISA) {#sec013}

Sera collected from all experimental and control mice following each immunization were analyzed for antigen-specific IgG by ELISA as previously described \[[@pone.0232355.ref025]\]. Briefly, plates coated with 0.25 μg/well of r*Pf*s25, r*Pf*s25/8 or r*Pf*MSP8 were incubated with two-fold dilutions of mouse sera for two hours at room temperature. Bound antibodies were detected by HRP-conjugated rabbit anti-mouse IgG (0.08 μg/ml; ThermoFisher Scientific) and ABTS \[2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)\] as substrate. *A*~405~ values between 0.1 and 1 were plotted and titers were calculated as the reciprocal of the dilution yielding an *A*~405~ of 0.5. A high titer pool of sera obtained from r*Pf*s25/8-immunized mice was included on every plate to normalize data between plates.

### IgG subclass profiles of antigen-specific antibodies {#sec014}

To determine the IgG subclass profiles of antigen-specific IgG, tertiary immunization serum from each mouse was titered, as described above, in wells coated with r*Pf*s25/8. Bound antibodies were detected by HRP-conjugated rabbit anti-mouse IgG specific for subtypes IgG1, IgG2a, IgG2b, IgG2c and IgG3 (Southern Biotech, Inc., Birmingham, AL.) followed by ABTS substrate. To generate a standard curve, each plate included wells coated with 2-fold dilutions of subtype-specific mouse myeloma immunoglobulin at known concentrations. Here, IgG subclass quantities in sera are reported as units/ml (U/ml) where 1 U/ml is equivalent to the signal obtained with 1 μg/ml of purified myeloma protein.

Standard membrane feeding assay {#sec015}
-------------------------------

The transmission-reducing activity (TRA) of IgG antibodies induced by each vaccine formulation was measured by a Standard Membrane Feeding Assay (SMFA) using cultured *P*. *falciparum* NF54 gametocytes and *Anopheles stephensi* mosquitoes, as previously described \[[@pone.0232355.ref041]\]. Pools of protein G-purified, vaccine-induced IgG (750 μg/ml) were mixed with stage V gametocytes and fed to *A*. *stephensi* mosquitoes through a membrane feeding apparatus. Mosquitoes were kept for 8 days prior to dissection to quantify midgut oocysts. Percent inhibition of mean oocyst intensity was calculated relative to adjuvant control IgG. The best estimate of % inhibition in mean oocyst density (% TRA), the 95% confidence interval, and the *p*-value (whether the observed %TRA is significantly different from no inhibition) of each test sample were calculated using a zero-inflated negative binomial model \[[@pone.0232355.ref042]\].

Statistical analysis {#sec016}
--------------------

All statistical analyses conducted in this study were nonparametric. To assess T cell responses (proliferation and cytokine production) in antigen-immunized groups relative to the corresponding control group, a Kruskal-Wallis test was conducted. To assess boosting of antigen-specific IgG responses within the same animals following each immunization, a Friedman's test for multiple repeated samples followed by a Dunn's post hoc test was utilized. For analysis of final anti-*Pf*s25 titers induced by immunization with r*Pf*s25, r*Pf*s25 + r*Pf*MSP8, or r*Pf*s25/8 in the different dose and adjuvant formulations, a Kruskal-Wallis test followed by a Dunn's post hoc test was performed. Instances in which two unrelated groups were directly compared, Mann-Whitney *U* tests were used. In all cases, differences with a probability (*p)* value of \<0.05 were considered significant.

Results {#sec017}
=======

The relative immunogenicity of the two recombinant *Pf*s25-based vaccines, unfused r*Pf*s25 and chimeric r*Pf*s25/8, was compared as a function of various vaccine parameters including antigen form (r*Pf*s25, r*Pf*s25/8 or an admixture of r*Pf*s25 + r*Pf*MSP8), antigen dose and adjuvant selection. Antibody responses induced by each vaccine formulation were measured with respect to magnitude, specificity, IgG subclass and functionality. In addition, the phenotype and specificity of vaccine-induced T cells were assessed.

*Pf*s25 and *Pf*MSP8 domains elicit antigen-specific T cell responses {#sec018}
---------------------------------------------------------------------

The domain specificity of T cell responses elicited by immunization with r*Pf*s25 and r*Pf*s25/8 antigens was determined. To this end, splenocytes from immunized animals were harvested and stimulated *in vitro* with r*Pf*s25, r*Pf*MSP8, or r*Pf*s25/8 antigens. Additional sets were stimulated with Concanavalin A (Con A) or left unstimulated to serve as positive and negative controls, respectively. Proliferative responses of antigen-specific T cells were determined using a standard \[^3^H\]-thymidine incorporation assay.

As shown in [Fig 1(A)--1(D)](#pone.0232355.g001){ref-type="fig"}, T cells from all groups immunized with any formulation containing r*Pf*MSP8 (r*Pfs25* + *Pf*MSP8 admixture, r*Pf*s25/8, r*Pf*MSP8) demonstrated similar and strong proliferative responses when stimulated with r*Pf*MSP8; all were significantly higher than those observed by cells from corresponding adjuvant control mice. This was true irrespective of antigen dose or adjuvant. Similarly, T cells from groups immunized with *Pf*s25-containing formulations (r*Pf*s25 alone, r*Pfs25* + *Pf*MSP8 admixture, r*Pf*s25/8) demonstrated similar and specific proliferative responses when stimulated with r*Pf*s25 that were significantly higher than corresponding control mice. Again, this was true irrespective of antigen dose or adjuvant, with one exception. Proliferation of T cells from mice immunized with 2.5 μg of r*Pf*s25/8 formulated with GLA-SE and stimulated in vitro with r*Pf*s25 was low and not significantly different relative to adjuvant control mice ([Fig 1C](#pone.0232355.g001){ref-type="fig"}). This could potentially be due to a shift of the T cell response toward epitopes in r*Pf*MSP8 at the higher dose. With Alum-based formulations, the slightly higher than expected proliferation of cells from r*Pf*s25-vaccinated mice when stimulated with r*Pf*MSP8 and vice versa ([Fig 1A and 1B](#pone.0232355.g001){ref-type="fig"}) may be due to a shared epitope(s) between the two antigens associated with a common leader and linker sequence. As expected, cells harvested from all antigen-immunized mice demonstrated high proliferative responses when stimulated with chimeric r*Pf*s25/8 ([S1 Fig](#pone.0232355.s001){ref-type="supplementary-material"}). These were generally additive of the domain-specific responses. Collectively, these data demonstrate that T cells from CB6F1/J immunized mice recognize epitopes present in both *Pf*s25 and *Pf*MSP8 domains.

![Both r*Pf*s25 and r*Pf*MSP8 domains elicit antigen-specific T cell responses irrespective of vaccine formulation.\
Splenocytes (2 x 10^5^/ well) harvested from groups of CB6F1/J mice immunized as indicated were stimulated *ex vivo* in triplicate with r*Pf*MSP8 (2 μg/ well) or r*Pf*s25 (2 μg/ well) for 96 hrs. Additional sets were stimulated with Con A (0.2 μg/well) or incubated in normal media as positive and negative controls, respectively. \[^3^H\]-thymidine (1 μCi/ well) was added for the final 18 hours. Average counts of incorporated \[^3^H\]-thymidine were measured for each stimulation condition and converted into a Stimulation Index (SI) that represents the fold change in proliferation of the indicated condition over the corresponding control wells (media alone). Graphs depict the mean SI +/- standard deviation. Asterisks directly over a single bar represent significant differences between the indicated groups relative to the corresponding adjuvant control group (Kruskal-Wallis Test; *P* \< 0.05 considered significant). Asterisks over horizontal lines indicate significant differences between the two groups (Mann-Whitney *U* Test; *P* \< 0.05 considered significant).](pone.0232355.g001){#pone.0232355.g001}

Antigen-specific T cells induced by Alum- and GLA-SE-based formulations are skewed toward Th~2~ and Th~1~ profiles, respectively, in a *Pf*MSP8-dependent manner {#sec019}
----------------------------------------------------------------------------------------------------------------------------------------------------------------

The effect of adjuvant on the type of antigen-specific T helper cells (Th~1~ vs. Th~2~) induced by immunization was evaluated based on cytokine production following antigen re-exposure. Similar to the T cell proliferation studies, splenocytes were collected and stimulated *in vitro* with r*Pf*s25, r*Pf*s25/8, r*Pf*MSP8 or cultured in media alone. Stimulation with Con A served as a positive control. Culture supernatants were collected and analyzed for production of IL-5, TNFα, IFNγ, IL-2 and IL-4 via a multiplex assay (Luminex). As expected, stimulation with Con A elicited detectible and similar responses in cells from all groups ([S1 Table](#pone.0232355.s005){ref-type="supplementary-material"}). As shown in [Fig 2](#pone.0232355.g002){ref-type="fig"}, cells from most antigen-immunized groups secreted detectible levels of IL-5, IFNγ and TNFα when stimulated with r*Pf*s25/8. However, there was a clear effect of adjuvant on the relative level of each of these cytokines.

![Cytokine production by CD4^+^ T cells reveals different T helper profiles as a function of adjuvant in a *Pf*MSP8-dependent manner.\
Splenocytes (5 x 10^5^/well) were harvested from groups of CB6F1/J mice immunized as indicated and stimulated *ex vivo* in the presence of r*Pf*s25/8 (2 μg/well) or in media alone for 96 hours. Culture supernatants were collected and analyzed for production of **A)** IL-5, **B)** IFNγ and **C)** TNFα using a multiplex assay (Luminex^®^). To calculate the final concentration of each analyte, levels found in the corresponding unstimulated conditions were subtracted as background. Graphs depict the mean concentration of each analyte +/- standard deviation. Asterisks directly over single bars represent significant differences between the indicated groups compared to the corresponding adjuvant control group (Kruskal-Wallis Test; *P* \< 0.05 considered significant). Asterisks over horizontal lines signify significant differences between the two indicated groups (Mann-Whitney *U* test; *P* \< 0.05 considered significant; ns, not significant).](pone.0232355.g002){#pone.0232355.g002}

Irrespective of antigen dose, T cells from groups immunized with Alum-based formulations produced primarily IL-5 ([Fig 2A](#pone.0232355.g002){ref-type="fig"}). These levels were similar for all formulations containing *Pf*MSP8 and significantly higher compared to levels produced by T cells from Alum control mice. Of interest, cells from groups immunized with r*Pf*s25 formulated in Alum produced only low levels of IL-5, not significantly different than adjuvant control mice.

The response of T cells from mice immunized with vaccines formulated with GLA-SE was robust at both antigen doses and marked by a more diversified cytokine profile ([Fig 2](#pone.0232355.g002){ref-type="fig"}). Cells from mice immunized with *Pf*MSP8-containing vaccines with GLA-SE as adjuvant produced IL-5 at significantly higher levels relative to the control group ([Fig 2A](#pone.0232355.g002){ref-type="fig"}). Of note, cells from mice immunized with unfused r*Pf*s25 formulated with GLA-SE produced low levels of IL-5 that were not statistically above background controls. In pairwise comparisons, the IL-5 levels elicited by GLA-SE-based formulations were similar to those produced by the corresponding Alum-based formulations at both doses. In contrast, groups immunized with *Pf*MSP8-containing vaccines formulated with GLA-SE also produced both IFNγ ([Fig 2B](#pone.0232355.g002){ref-type="fig"}) and TNFα ([Fig 2C](#pone.0232355.g002){ref-type="fig"}) at levels significantly higher than the corresponding Alum-based antigen groups and GLA-SE controls. This was not true for cells from mice immunized with unfused r*Pf*s25 in GLA-SE, which did not produce significant quantities of either IFNγ or TNFα.

The production of IL-2 and IL-4 by antigen-specific T cells was also assessed following stimulation with r*Pf*s25/8. Production of both analytes was low in all vaccine formulations, with no significant differences observed as a function of immunizing antigen, dose and/or adjuvant ([S2 Table](#pone.0232355.s006){ref-type="supplementary-material"}). The observation that cytokine production is adjuvant and carrier-dependent was further confirmed by results of domain-specific stimulation with r*Pf*MSP8 alone ([S2 Fig](#pone.0232355.s002){ref-type="supplementary-material"}) which yielded results similar to stimulation with r*Pf*s25/8. Therefore, in some contrast to the proliferative responses observed upon stimulation with both r*Pf*s25 and r*Pf*MSP8 domains, cytokine production was driven primarily by epitopes present in *Pf*MSP8 domain with choice of adjuvant influencing the profile.

Fusion of r*Pf*s25 to the *Pf*MSP8 carrier elicits strong anti-*Pf*s25 antibody responses and alleviates antigenic competition {#sec020}
------------------------------------------------------------------------------------------------------------------------------

It is well established that transmission-reducing activity of *Pf*s25-based vaccines is primarily antibody mediated. As such, the magnitude and specificity of the antibody responses induced by each vaccine formulation over time was evaluated. Sera were collected following each of three s.c. immunizations and domain-specific IgG titers determined. As depicted in [Fig 3A](#pone.0232355.g003){ref-type="fig"}, immunization with 2.5 μg dose of r*Pf*s25, r*Pf*s25 + r*Pf*MSP8, or r*Pf*s25/8 adjuvanted with Alum elicited strong and comparable anti-*Pf*s25 IgG titers that were significantly boosted over time. At the 0.5 μg dose in Alum ([Fig 3B](#pone.0232355.g003){ref-type="fig"}), high anti-*Pf*s25 IgG were also generated in response to immunization with r*Pf*s25. However, the anti-*Pf*s25 IgG response was impaired in mice immunized with the admixture of r*Pf*s25 + r*Pf*MSP8 relative to animals immunized with r*Pf*s25 alone, indicative of competition between r*Pf*s25 and r*Pf*MSP8 when administered as separate, non-fused components. Importantly, this competition was eliminated upon immunization with 0.5 μg of the chimeric r*Pf*s25/8 in Alum with a strong anti-*Pf*s25 IgG response comparable to that observed in the r*Pf*s25 group. Immunization with either dose of r*Pf*s25/8, the r*Pf*s25 + r*Pf*MSP8 admixture or *Pf*MSP8 antigens formulated in Alum induced strong and similar titers against the highly immunogenic r*Pf*MSP8 carrier, which were increased significantly over time ([Fig 3C and 3D](#pone.0232355.g003){ref-type="fig"}). Of note, antibodies induced by immunization with r*Pf*s25 alone exhibited some reactivity with r*Pf*MSP8 ([Fig 3C and 3D](#pone.0232355.g003){ref-type="fig"}). This reactivity is associated with a shared epitope(s) present within the His-tag and linker that are common to both antigens. This reactivity is relatively low, representing only 1--2% of the overall anti-*Pf*s25 titer induced by immunization with unfused r*Pf*s25 ([Fig 3A and 3B](#pone.0232355.g003){ref-type="fig"}).

![Antigen-specific IgG titers elicited by Alum-based formulations.\
CB6F1/J sera collected 3 weeks following each subcutaneous immunization were analyzed for antigen-specific antibodies by ELISA using plates coated with r*Pf*s25 **(A and B)** or *Pf*MSP8 **(C and D)** (0.25 μg/well). Graphs depict the mean IgG titers +/- standard deviation. Asterisks over horizontal lines within an immunization group indicate significant boosting of antigen-specific IgG titers over time (Friedman Test; *P* \< 0.05 considered significant). Asterisks over horizontal lines comparing different immunization groups indicate significant differences between final titers achieved by those groups (Kruskal Wallis Test, *P* \< 0.05 considered significant; ns, not significant).](pone.0232355.g003){#pone.0232355.g003}

Likewise, the anti-*Pf*s25 response induced by immunization with 2.5 μg of r*Pf*s25, r*Pf*s25 + r*Pf*MSP8 admixture or r*Pf*s25/8 formulated in GLA-SE was assessed ([Fig 4A](#pone.0232355.g004){ref-type="fig"}). Responses were detected in all groups that were significantly boosted over time. However, there was a 10-fold reduction in final anti-*Pf*s25 titer in mice immunized with the r*Pf*s25 + r*Pf*MSP8 admixture relative to the group immunized with r*Pf*s25 alone, highlighting competition between antigens. Importantly, this response was restored in mice immunized with the chimeric r*Pf*s25/8, resulting in a higher final titer relative to the r*Pf*s25 immunized mice group. Antibody responses elicited by immunization with these antigens formulated at 0.5 μg also increased significantly over time ([Fig 4B](#pone.0232355.g004){ref-type="fig"}). However, the anti-*Pf*s25 response elicited by r*Pf*s25 at the 0.5 μg dose was more than 10-fold lower than that induced at the 2.5 μg dose. Again, anti-*Pf*s25 titers were further decreased in the admixture group. Similar to the 2.5 μg dose group, immunization with chimeric r*Pf*s25/8 was able restore this response with final anti-*Pf*s25 titers even greater than those observed in mice immunized with unfused r*Pf*s25. Despite divergent responses against *Pf*s25, the anti-*Pf*MSP8 responses elicited in mice immunized with r*Pf*s25 + r*Pf*MSP8, r*Pf*s25/8 or r*Pf*MSP8 carrier alone formulated with GLA-SE were strong and comparable irrespective of dose and was significantly boosted over time ([Fig 4C and 4D](#pone.0232355.g004){ref-type="fig"}). Antibody titers measured against r*Pf*s25/8 coated wells were generally additive of the two individual domain-specific responses ([S3 Fig](#pone.0232355.s003){ref-type="supplementary-material"}).

![Antigen-specific IgG titers elicited by GLA-SE-based formulations.\
CB6F1/J sera collected 3 weeks following each subcutaneous immunization were analyzed for antigen-specific antibodies by ELISA using plates coated with r*Pf*s25 **(A and B)** or *Pf*MSP8 **(C and D)** (0.25 μg/well). Graphs depict the mean IgG titers +/- standard deviation. Asterisks over horizontal lines within an immunization group indicate significant boosting of antigen-specific IgG titers over time (Friedman Test; *P* \< 0.05 considered significant). Asterisks over horizontal lines comparing different immunization groups indicate significant differences between final titers achieved by those groups (Kruskal Wallis Test, *P* \< 0.05 considered significant).](pone.0232355.g004){#pone.0232355.g004}

Finally, the effectiveness of Alum vs GLA-SE as adjuvant in mice immunized with r*Pf*s25 or the chimeric r*Pf*s25/8 was considered. As shown in [Fig 5](#pone.0232355.g005){ref-type="fig"}, both r*Pf*25-containing vaccines induced high and comparable titers against *Pf*s25 when formulated with Alum irrespective of dose. However, there were significant differences in final titer induced by the two antigens when GLA-SE was used as an adjuvant. Here, the final anti-*Pf*s25 titer induced in the r*Pf*s25-immunized group was 10-fold lower than the corresponding group formulated with Alum. Importantly, chimeric r*Pf*s25/8 formulated with GLA-SE elicited significantly higher final titers of anti-*Pf*s25 IgG relative to immunization with unfused r*Pf*s25 at the same dose; these titers were comparable to those induced by Alum-based formulations. Together, these data indicate that Alum was an equally potent adjuvant for both vaccine antigens, while maximal anti-*Pf*s25 responses elicited by GLA-SE based formulations depended on genetic fusion of r*Pf*s25 to the r*Pf*MSP8 carrier protein.

![Final anti-*Pf*s25 IgG titers induced by immunization with r*Pf*s25 and r*Pf*s25/8 as a function of dose and adjuvant.\
Direct comparison of final anti-*Pf*s25 IgG titers induced by r*Pf*s25 vs chimeric r*Pf*s25/8 antigens when formulated as indicated. Graphs depict the mean IgG titers +/- standard deviation. Comparisons of two groups differing only by antigen identity were conducted and significant differences are indicated by asterisks over horizontal lines (Mann-Whitney *U* Test; *P* \< 0.05 considered significant). Comparisons of three or more groups were conducted as indicated and no significant differences were found (Kruskal Wallis Test, *P* \< 0.05 considered significant; ns, not significant).](pone.0232355.g005){#pone.0232355.g005}

Switch from Alum to GLA-SE as adjuvant for *Pf*s25-based vaccines shifts the B cell response to the production of cytophilic IgG in a *Pf*MSP8-dependent manner {#sec021}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

In addition to titer, the functionality of vaccine-induced IgG may be influenced by heavy chain subclass depending on adjuvant selection. The profile of IgG subclasses in the final sera from each vaccine group was measured by ELISA using plates coated with r*Pf*s25/8 and secondary antibodies specific for IgG1, IgG2a/c, IgG2b and IgG3. As shown in [Fig 6](#pone.0232355.g006){ref-type="fig"}, vaccines formulated with Alum, regardless of antigen or dose, elicited antibodies primarily of the IgG1 subclass, with low but detectible IgG2a/c, IgG2b and IgG3. In the same way, immunization with r*Pf*MSP8-containing vaccines formulated with GLA-SE, irrespective of dose, produced high and similar levels of IgG1 compared to the Alum-formulated counterparts. One exception was noted in the r*Pf*s25 + *Pf*MSP8 admixture group that showed a modest but statistically significant reduction in IgG1. In stark contrast to the IgG profiles induced by Alum-based formulations, mice immunized with GLA-SE-based formulations also produced significantly higher levels of antigen-specific IgG2a/c, IgG2b and IgG3 relative to the Alum-formulated counterparts. This was not true for r*Pf*s25-immunized animals, which primarily produced antigen-specific IgG1 when formulated with either Alum or GLA-SE. These results demonstrate a strong influence of adjuvant on IgG subtype profile generated in response to vaccination, with IgG class-switching in the GLA-SE formulations dependent on the presence of the r*Pf*MSP8 carrier.

![Profile of IgG subclasses of vaccine-induced IgG is dependent upon adjuvant and antigen.\
CB6F1/J sera harvested four weeks following the final immunization were analyzed for relative levels of the indicated IgG subclasses by ELISA using plates coated with r*Pf*s25/8 (0.25 μg/well). Graphs depict the mean IgG subclass concentration +/- standard deviation. Comparisons of two groups that differed by adjuvant only were conducted and asterisks over horizontal lines indicate significant differences between groups (Mann-Whitney *U* Test; *P* \< 0.05 considered significant; ns, not significant).](pone.0232355.g006){#pone.0232355.g006}

Transmission-reducing activity (TRA) of IgG induced by immunization with r*Pf*s25-based vaccines formulated with Alum vs GLA-SE {#sec022}
-------------------------------------------------------------------------------------------------------------------------------

In addition to the magnitude and profile of antibody responses, demonstrating the ability of *Pf*s25-containing vaccines to induce IgG that inhibits development of sexual-stage parasites in the mosquito vector is important. To test the relative functionality of IgG induced by r*Pf*s25 and r*Pf*s25/8 vaccines, total IgG was purified from pools of sera derived from each vaccine group and tested in the SMFA at a concentration of 750 μg/ml. As depicted in [Table 1](#pone.0232355.t001){ref-type="table"}, all Alum-based formulations elicited potent and comparable TRA relative to the IgG derived from adjuvant-immunized control groups. Similarly, IgG from r*Pf*s25/8 + GLA-SE immunized groups also demonstrated potent TRA relative to control IgG. As predicted based on analysis of anti-*Pf*s25 antibody responses, groups immunized with r*Pf*s25 formulated with GLA-SE had much lower TRA that were not statistically different from controls.

10.1371/journal.pone.0232355.t001

###### Transmission-reducing activity of vaccine-induced IgG is a function of antigen and adjuvant.

![](pone.0232355.t001){#pone.0232355.t001g}

  Immunization Group          IgG level (μg/ml)   Transmission-reducing activity                                  
  --------------------------- ------------------- -------------------------------- ------ ------- ------- ------- -------
  **Adjuvant Control Sera**   N/A                 N/A                              750    0                       
  **Alum**                    **r*Pf*s25**        **2.5 μg**                       750    100.0   98.7    100.0   0.001
  **r*Pf*s25/8**              **2.5 μg**          750                              99.3   97.5    100.0   0.001   
  **r*Pf*s25**                **0.5 μg**          750                              99.3   97.6    100.0   0.001   
  **r*Pf*s25/8**              **0.5 μg**          750                              98.0   95.4    99.5    0.001   
  **GLA-SE**                  **r*Pf*s25**        **2.5 μg**                       750    46.5    -23.1   75.5    0.128
  **r*Pf*s25/8**              **2.5 μg**          750                              97.4   90.1    100.0   0.001   
  **r*Pf*s25**                **0.5 μg**          750                              46.5   -25.8   79.5    0.135   
  **r*Pf*s25/8**              **0.5 μg**          750                              89.4   75.4    95.9    0.001   

Total IgG from pools of tertiary sera collected from CB6F1/J mice immunized with r*Pf*s25 or r*Pf*s25/8 formulated as indicated was purified and tested in a standard membrane feeding assay at a concentration of 750 μg/ml. Each IgG sample was fed to 20 mosquitos. The best estimates and 95% confidence intervals (CIs) of percent inhibitions and *P* values were calculated for each pool compared to IgG derived from adjuvant-immunized control mice.

### Bivalent formulations containing r*Pf*s25/8 and r*Pf*MSP1/8 elicit strong antibody titers against both fusion partners in outbred mice, with no indication of antigen competition {#sec023}

Based on the above immunogenicity and functionality data, chimeric r*Pf*s25/8 was evaluated in combination with r*Pf*MSP1/8, which elicits potent merozoite invasion inhibitory antibodies. The immunogenicity of r*Pf*s25/8 + r*Pf*MSP1/8 (2.5 μg each antigen/dose) was compared to corresponding monovalent vaccines (2.5 μg/dose) when adjuvanted with Alum or GLA-SE. Immunizations were conducted in male (n = 5) and female (n = 5) outbred (CD1) mice in order to i) assess the consistency of vaccine-induced responses in a genetically diverse population, ii) evaluate sex as a variable with potential to influence immune responses, and iii) determine the impact of concurrent immunization with two subunit vaccines fused to the same r*Pf*MSP8 carrier. Mice were immunized three times and sera collected following each immunization. These samples were then analyzed for antigen-specific titers against both *Pf*s25 and *Pf*MSP1~19~ fusion partners, well as the *Pf*MSP8 carrier.

As shown in [Fig 7A--7C](#pone.0232355.g007){ref-type="fig"}, all antigen-immunized groups mounted strong antigen-specific antibody response against component domains contained in the formulation (*Pf*MSP1~19~, *Pf*s25, and/ or *Pf*MSP8). These antigen-specific antibody responses were significantly boosted over time in all groups. Importantly, final domain-specific IgG titers elicited by immunization with the bivalent formulations were comparable to those induced by the corresponding monovalent vaccines, regardless of adjuvant or antigen ([Fig 7](#pone.0232355.g007){ref-type="fig"}). Following three immunizations, the anti-*Pf*MSP1~19~ and anti-*Pf*s25 titers in male and female mice in each immunization group were comparable, indicating that host sex did not influence vaccine immunogenicity ([S4 Fig](#pone.0232355.s004){ref-type="supplementary-material"}). Overall, these data indicate that concurrent responses against B cell determinants within two different *Pf*MSP8 fusion partners can be effectively induced by a bivalent vaccine without antigenic competition.

![Bivalent formulations containing r*Pf*s25/8 and r*Pf*MSP1/8, irrespective of adjuvant, elicit strong titers against both fusion partners with no indication of antigen competition relative to corresponding monovalent vaccines.\
Sera harvested from groups of CD1 mice (5 male, 5 female) immunized as indicated were analyzed for antigen-specific IgG by ELISA using plates coated with **A)** r*Pf*s25, **B)** rGST-*Pf*MSP1~19~ or **C)** r*Pf*MSP8 (0.25 μg/well). Sera from each adjuvant control group were measured against the corresponding chimeric antigen (r*Pf*s25/8 or r*Pf*MSP1/8). Graphs depict mean IgG titers +/- standard deviation. Asterisks over horizontal lines within an immunization group indicate significant boosting of antigen-specific responses over time (Friedman Test; *P* \< 0.05 considered significant). Final IgG titers induced against each component in the bivalent formulations were compared to the corresponding monovalent group (Mann-Whitney *U* test; *P \<* 0.05 considered significant; ns, not significant).](pone.0232355.g007){#pone.0232355.g007}

The effect of adjuvant on the domain-specific IgG titers induced by each antigen formulation was compared. As shown in [Fig 8](#pone.0232355.g008){ref-type="fig"}, the magnitude of the anti-*Pf*s25 response was high and comparable in monovalent vs. bivalent vaccines, and similar between Alum- and GLA-SE-based formulations. These findings indicate that immunization with r*Pf*s25/8 induces strong anti-*Pf*s25 responses that are independent of adjuvant selection and are not inhibited by the presence of r*Pf*MSP1/8 in the formulation. In contrast, anti-*Pf*MSP1~19~ titers induced by the bivalent vaccine were significantly higher when formulated with GLA-SE vs. Alum. In addition, responses to the *Pf*MSP8 carrier were significantly higher when formulated with GLA-SE vs. Alum across all immunization groups. As such, the strength of anti-*Pf*MSP1~19~ titers generated by immunization with r*Pf*MSP1/8 was dependent upon adjuvant, with GLA-SE-based formulations inducing superior responses.

![Final antigen-specific IgG titers elicited in monovalent and bivalent vaccine formulations as a function of adjuvant.\
Titers of antigen-specific IgG following the final subcutaneous immunization were measured for each group via ELISA using plates coated with r*Pf*s25 or rGST-*Pf*MSP1~19~ (0.25 μg/well). Graphs depict mean IgG titers +/- standard deviation. To assess the effect of adjuvant on the IgG titer, direct comparisons were made between corresponding antigen groups formulated with either Alum or GLA-SE. Asterisks over horizontal lines indicate significant differences between indicated groups (Mann-Whitney *U* test; *P \<* 0.05 considered significant; ns, not significant).](pone.0232355.g008){#pone.0232355.g008}

As above, the profile of anti-*Pf*MSP8 IgG induced by each formulation was evaluated to determine the relative levels of IgG1, IgG2a/c, IgG2b and IgG3 subtypes. As shown in [Fig 9](#pone.0232355.g009){ref-type="fig"}, strong and similar levels of IgG1 were detected in all groups regardless of antigen formulation or adjuvant. All Alum-based formulations induced detectible but very low levels of IgG2a/c and IgG2b, consistent with the expected Th~2~ associated response. In contrast, strong and significant production of IgG2a/c, IgG2b and IgG3 was observed in all GLA-SE-based formulations. These data confirm results from studies in inbred mice with vaccines utilizing *Pf*MSP8 as a carrier ([Fig 6](#pone.0232355.g006){ref-type="fig"}), showing that the production of cytophilic IgG occurs in the context of the Th~1~-baising adjuvant, GLA-SE, and leads to a more diverse IgG subclass profile.

![Profile of IgG subclasses of vaccine-induced IgG is dependent upon adjuvant and antigen.\
Sera harvested four weeks following the final immunization were analyzed for relative levels of the indicated subclasses of IgG via ELISA using plates coated with r*Pf*MSP8 (0.25 μg/well). Graphs depict mean IgG subclass concentration (U/ml) +/- standard deviation. Comparisons of two corresponding groups that differed by adjuvant only were conducted and asterisks over horizontal lines indicate significant differences between groups (Mann-Whitney *U* Test; *P* \< 0.05 considered significant).](pone.0232355.g009){#pone.0232355.g009}

Discussion {#sec024}
==========

Though conceptually simple, the rational production of a multivalent, multistage subunit malaria vaccine is a challenge. The first requirement is that recombinant forms of each component be produced so that they bear proper conformation and induce antibodies that demonstrate functionality against the targeted stage(s) of plasmodial parasites. The production of recombinant antigens with routine heterologous expressions systems has often resulted in low yields and/or inconsistent, misfolded products incapable of producing protective antibodies to neutralizing, conformational B cell epitopes. \[[@pone.0232355.ref043]--[@pone.0232355.ref046]\]. This is true for *Pf*s25, but transmission blocking antibodies have been induced by r*Pf*s25 produced in scalable yeast \[[@pone.0232355.ref043], [@pone.0232355.ref047], [@pone.0232355.ref048]\] and baculovirus \[[@pone.0232355.ref049]\] systems and recently with a non-glycosylated, folded product of an *E*. *coli* expression system \[[@pone.0232355.ref050]\].

An equally important impediment to overcome is the inherently poor immunogenicity of many malaria vaccine candidates. This is often attributed to the small size of the antigen or, more often, the inability to elicit effective CD4^+^ T cell responses capable of providing adequate help to B cells for the production of protective antibodies. In some cases, this deficit may be due to a lack of immunogenic CD4^+^ T cell epitopes. However, it may also be due to the presence of complex tertiary structures that inhibit antigen processing and presentation, such as highly constrained EGF-like domains. This appears to be the case for *Pf*MSP1~19~ \[[@pone.0232355.ref051], [@pone.0232355.ref052]\]. Further complicating the task is the need to induce protective and durable responses against each component that can be maintained when formulated in a multiantigen combination. Antigenic competition between co-administered components has been noted in several studies \[[@pone.0232355.ref004]--[@pone.0232355.ref006]\]. In the recent Phase III RTS,S trial, one of several contributing factors to lower responses in children compared to adults may relate to the administration of RTS,S concurrently with other childhood vaccines through the Expanded Program for Immunization (EPI) \[[@pone.0232355.ref053], [@pone.0232355.ref054]\].

Common strategies to address issues relating to immunogenicity, include i) use of heterologous carrier proteins, ii) formulation with potent adjuvants, and iii) optimization of vaccine dose, route of administration and/ or timing of vaccinations. These considerations, as well as the nature of the target itself, are likely to impact overall immunogenicity of a given formulation. Variations of these parameters were evaluated in an effort to improve the efficacy and duration of responses generated by immunization with the *Pf*s25-Exoprotein A conjugate \[[@pone.0232355.ref055]\], the leading *Pf*s25-based clinical candidate. Results of those studies indicated that anti-*Pf*s25 responses were influenced by both adjuvant and specific carrier selected \[[@pone.0232355.ref055]\]. Similarly, our comparative immunogenicity studies indicate that the induction of potent anti-*Pf*s25 responses is significantly influenced by the presence of the *Pf*MSP8 carrier as well as by adjuvant formulation.

We began a systematic evaluation of our candidate antigens by assessing how these parameters affected cellular responses. Using a \[^3^H\]-thymidine incorporation assay to determine the specificity of vaccine-induced cellular responses, we showed that immunization with any of the *Pf*MSP8-containing vaccines induced significant and similar levels of antigen-specific T cell proliferation against *Pf*MSP8. This was expected, as previous studies conducted in both inbred and outbred mice demonstrated the presence of potent CD4^+^ T cell epitopes within the *Pf*MSP8 carrier \[[@pone.0232355.ref024], [@pone.0232355.ref025]\]. Interestingly, proliferative responses against *Pf*s25 were also detected following immunization with all three r*Pf*s25-containing vaccines, though at a lower magnitude relative to *Pf*MSP8. Nevertheless, this indicated that *Pf*s25 possesses one or more MHC II epitopes capable of inducing *Pf*s25-specific CD4^+^ T cell responses in mice, even in the absence of a carrier. Indeed, *Pf*s25 contains at least one epitope predicted to bind MHC II. Unlike *Pf*MSP1~19~, the CD4^+^ epitope(s) within *Pf*s25 appear(s) to be available for processing and presentation despite the highly constrained nature of this antigen. The specificity of CD4^+^ T cells induced by these formulations was not affected by adjuvant selection.

The phenotype of T cells generated in response to *Pf*s25-based vaccines was influenced by adjuvant. Alum-based formulations containing r*Pf*s25/8, regardless of dose, elicited significant levels of Th~2~-associated cytokine, IL-5, and very low levels of Th~1~-associated cytokines, IFNγ and TNFα. This was expected, as Alum is a known Th~2~-biasing adjuvant. Downstream analysis of the IgG subclasses induced by vaccines adjuvanted with Alum reflected this Th~2~-biasing effect, as the vast majority of antigen-specific antibodies were IgG1. Vaccines formulated with GLA-SE, an adjuvant known to drive responses to a Th~1~ phenotype, elicited T cells that produced significantly elevated levels of Th~1~-associated IFNγ and TNFα in comparison to Alum-based formulations, in a *Pf*MSP8-dependent manner. These T cells also produced IL-5 at similar levels to those achieved by Alum-based formulations. However, the elevated levels of Th~1~-associated cytokines in GLA-SE based formulations influenced downstream class switching, leading to a more diversified IgG profile of antigen-specific antibodies that featured significant increases in cytophilic IgG2a/c, as well as IgG2b and IgG3.

We assessed the domain-specific responses of total IgG induced by the various vaccine formulations as an indicator of potential efficacy. All formulations containing r*Pf*MSP8 resulted in high and comparable titers of anti-*Pf*MSP8 IgG irrespective of adjuvant or dose. However, the induction of optimal anti-*Pf*s25 humoral immunity was dependent on both carrier and adjuvant. Consistent with the proliferation data, immunization with r*Pf*s25 elicited high anti-*Pf*s25 antibody titers when formulated with Alum at both antigen doses. In contrast, only modest titers of anti-*Pf*s25 IgG were elicited by unfused r*Pf*s25 when formulated with GLA-SE, despite the detection of proliferative T cell responses in these groups. These results differ from a previous study in which *Chlamydomonas reinhardtii-*produced r*Pf*s25 formulated with GLA-SE effectively induced anti-*Pfs25* antibodies that exhibited transmission-reducing activity in the SMFA \[[@pone.0232355.ref056]\]. However, this discrepancy may be a result of significant differences in the total amount of r*Pf*s25 administered in the two studies (50 μg vs 7.5 μg). In three of the four groups immunized with the admixture of r*Pf*s25 and r*Pf*MSP8, we observed a notable reduction in anti-*Pfs25* titers. These data indicate that antigenic competition is a potential problem and responses to r*Pf*s25 may be impaired by the presence of additional immunogenic vaccine components.

In agreement with our previous r*Pf*MSP1/8 studies, immunization with r*Pf*s25/8 elicited strong humoral responses against both the carrier and *Pf*s25 domains, effectively rescuing the anti-*Pfs25* response. This was true when r*Pf*s25/8 was formulated with Alum, where the anti-*Pf*s25 responses were restored to levels similar to those achieved by unfused r*Pf*s25. The improvement was even more pronounced when r*Pf*s25/8 was formulated with GLA-SE. Here, anti-*Pf*s25 IgG titers were enhanced relative to the modest titers achieved by r*Pf*s25 formulated with GLA-SE. In fact, the 2.5 μg dose of r*Pf*s25/8 formulated with GLA-SE elicited anti-*Pf*s25 responses comparable to those induced by either *Pf*s25-based antigen when formulated with Alum. Importantly, the anti-*Pf*s25 IgG induced by either *Pf*s25-based vaccine demonstrated potent transmission-reducing activity, irrespective of notable differences in IgG subclass profile. Consistent with previous reports \[[@pone.0232355.ref057]\], the magnitude of the anti-*Pf*s25 response primarily influenced transmission-reducing activity. Mice immunized with r*Pf*s25 formulated with GLA-SE displayed only modest anti-*Pf*s25 IgG responses with little or no functional activity. Together, these results showed that the genetic fusion of *Pf*s25 to the *Pf*MSP8 carrier was required for i) induction of anti-*Pf*s25 responses in the presence of additional immunogenic targets in a multivalent formulation and ii) induction of anti-*Pfs*25 IgG with functional activity in the context of a GLA-SE-based vaccine formulation. Furthermore, we observed potent transmission-reducing activity of vaccine-induced IgG at a concentration of 750 μg/ml, a value 1- to 3-fold lower than the normal level of IgG in mouse serum. These data increase the likelihood that immunization of human subjects with *Pf*s25/8 formulated with GLA-SE can induce functional antibodies that significantly impact parasite transmission if comparable vaccine immunogenicity is achieved.

Initial testing of a bivalent vaccine containing r*Pf*s25/8 and r*Pf*MSP1/8 in outbred mice demonstrated the induction of strong B cell responses against both *Pf*s25 and *Pf*MSP1~19~ that were comparable to those induced by corresponding monovalent vaccines. Anti-*Pfs*25 responses induced by r*Pf*s25/8 were strong and similar regardless of adjuvant selection or the presence of r*Pf*MSP1/8. Interestingly, anti-*Pf*MSP1~19~ responses induced by immunization with the bivalent vaccine were adjuvant dependent, with the GLA-SE-based formulations eliciting superior responses relative to the Alum-based formulations. This is reflective of several clinical trials in which *rPf*MSP1~42~ formulated with Alum resulted in suboptimal anti-*Pf*MSP1 responses \[[@pone.0232355.ref019], [@pone.0232355.ref058]\]. In addition to the lack of antigenic interference with either adjuvant formulation, these studies also showed that *Pf*MSP8 can be effectively used as a carrier for two distinct vaccine components when administered in the same formulation to genetically heterogeneous, male and female mice.

The systematic evaluation of immune responses generated by the two *Pf*s25-based vaccines as a function of various formulation parameters informed the selection of r*Pf*s25/8 as the more effective candidate. This was most apparent for the induction of transmission-blocking immunity particularly when GLA-SE was selected as adjuvant. In addition, results of the bivalent study suggest that anti-*Pf*MSP1~19~ responses are superior when formulated with GLA-SE, providing some incentive for ultimate selection of this adjuvant. The results of our ongoing comparative immunogenicity studies with inclusion of additional antigens such as *Pf*MSP2 into the multivalent formulation will also impact the choice of adjuvant for advanced testing. With *Pf*MSP2-containing vaccines, we expect that adjuvants such as GLA-SE will be required to effectively induce cytophilic IgG that is needed for opsonization and phagocytosis of merozoites. Overall, these studies further demonstrate the value of *Pf*MSP8 as a carrier protein to help induce effective humoral responses against protective, but poorly immunogenic vaccine components, targeting both blood-stage and sexual stage malaria parasites.

Supporting information {#sec025}
======================

###### Proliferative responses elicited following stimulation with r*Pf*s25/8 antigen.

CB6F1/J splenocytes (2 x 10^5^/ well) harvested from the indicated immunization groups were stimulated *ex vivo* in triplicate with r*Pf*s25/8 (2 μg/ well) for 96 hrs. \[^3^H\]-thymidine (1 μCi/ well) was added for the final 18 hours. Average counts of incorporated \[^3^H\]-thymidine were measured for r*Pf*s25/8-stimulated wells and converted into a Stimulation Index (SI) that represents the fold change in proliferation of the indicated condition over the corresponding control wells (media alone). Graphs depict mean SI +/- standard deviation.

(DOCX)

###### 

Click here for additional data file.

###### Profile of cytokines elicited following stimulation with r*Pf*MSP8.

CB6F1/J splenocytes (5 x 10^5^/well) were harvested from the indicated immunization groups and stimulated *ex vivo* in triplicate with r*Pf*MSP8 (2 μg/well) or in media alone for 96 hours. Culture supernatants were collected and analyzed for production of IL-5, IFNγ, TNFα, -4 and IL-2 using a multiplex assay (Luminex^®^). To calculate the final concentration of each analyte, the levels found in the corresponding unstimulated conditions were subtracted out as background. Graphs depict mean concentration of each analyte +/- standard deviation.

(DOCX)

###### 

Click here for additional data file.

###### Anti-r*Pf*s25/8 IgG titers induced by the indicated r*Pf*s25 containing vaccine formulations.

CB6F1/J sera collected 3 weeks following each subcutaneous immunization were analyzed for antigen-specific IgG via ELISA using plates coated with r*Pf*s25/8 (0.25 μg/well). Graphs depict mean IgG titers +/- standard deviation. Asterisks over bars within groups indicate significant boosting of antigen-specific responses over time (Friedman Test; *P* \< 0.05 considered significant).

(DOCX)

###### 

Click here for additional data file.

###### Evaluation of the effect of sex on humoral responses to immunization with combined formulations of r*Pf*s25/8 and r*Pf*MSP1/8 vaccines.

CD1 mice (10/group with 5 male and 5 female mice) were immunized as indicated and sera were collected following the third immunization. Titers of antigen-specific IgG were measured by ELISA with plates coated with r*Pf*s25 or rGST-*Pf*MSP1~19~ (0.25 ug/well). Graph depicts mean IgG titers +/- standard deviation. Antibody responses in male and female mice within the same immunization group were compared. Statistical significant of differences between sexes were evaluated (Mann-Whitney *U* Test; *P* \< 0.05 considered significant; ns, not significant).

(DOCX)

###### 

Click here for additional data file.

###### Cytokine production by cells from mice immunized with *Pf*s25-based vaccines in response to stimulation with Con A.

Splenocytes (5 x 10^5^/well) were harvested from groups of CB6F1/J mice (n = 5) immunized as indicated and stimulated ex vivo with Con A (0.2 μg/well) or cultured in media alone for 96 hours. Culture supernatants were collected and analyzed for production of IL-5, IFNγ, TNFα, IL-2 and IL-4 using a multiplex assay (Luminex^®^). To calculate the final concentration of each analyte, the levels found in the corresponding unstimulated conditions were subtracted as background. (ND = not detected).

(DOCX)

###### 

Click here for additional data file.

###### Production of IL-2 and IL-4 by cells from mice immunized with *Pf*s25-based vaccines in response to stimulation with r*Pf*s25/8.

Splenocytes (5 x 10^5^/well) were harvested from groups of CB6F1/J mice (n = 5) immunized as indicated and stimulated with ex vivo with r*Pf*s25/8 (2 μg/well) or cultured in media alone for 96 hours. Culture supernatants were collected and analyzed for production of IL-2 and IL-4 using a multiplex assay (Luminex^®^). To calculate the final concentration of each analyte, the levels found in the corresponding unstimulated conditions were subtracted as background. (ND = not detected).

(DOCX)

###### 

Click here for additional data file.

We thank Dr. Jacqueline Eacret (Drexel University) for critical review of the manuscript.

10.1371/journal.pone.0232355.r001

Decision Letter 0

Blagborough

Andrew M.

Academic Editor

© 2020 Andrew M. Blagborough

2020

Andrew M. Blagborough

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

3 Mar 2020

PONE-D-19-31841

Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination

PLOS ONE

Dear Dr. Burns, Jr.,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Apr 12 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Andrew M. Blagborough

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Competing Interests section:

\"I have read the journal\'s policy and the authors of this manuscript have the following competing interests:

JMB is an inventor listed on US Patent No. 7,931,908 entitled "Chimeric MSP-Based Malaria Vaccine".

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

3\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

4\. Please note that all PLOS journals ask authors to adhere to our policies for sharing of data and materials: <https://journals.plos.org/plosone/s/data-availability>. According to PLOS ONE's Data Availability policy, we require that the minimal dataset underlying results reported in the submission must be made immediately and freely available at the time of publication. As such, please remove any instances of \'unpublished data\' or \'data not shown\' in your manuscript and replace these with either the relevant data (in the form of additional figures, tables or descriptive text, as appropriate), a citation to where the data can be found, or remove altogether any statements supported by data not presented in the manuscript.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: in combination with PfMSP1/8 with the goal that each component maintains their immunogenicity. The goal is to generate a bivalent vaccine designed to target both malaria blood and sexual stages. The authors were successful in achieving this goal.

The introduction was well written.

Figure 1: The authors concluded that both Pfs25 and Pfs28 domains induce antigen-specific T cell response regardless of the vaccine formulation. Whilst they appear not significant, some responses appear higher than they should be (e.g. 2.5 ug dose -- anti-PfMSP8 response in the Pfs25-vaccinated mice, anti- Pfs25 response in the PfMSP8-vaccinated mice; and in some other groups -- whilst responses in the alum or GLA-SE only groups really showed poor responses). Could the authors comment on this? What could be causing the residual responses? The authors say that graphs depict mean SI +/- SD -- how many wells/group? The anti-Pfs25 response seems to be lower in the Pfs25/8 formulation with GLA-SE than the other groups in the 2.5ug dose. Why is this so?

Figure 2. The authors showed cytokine production by CD4+ T cells following vaccination. The methodology indicated that the authors also looked at IL-2 and IL-4, but no data was provided for these cytokines.

Figures 3 and 4. The authors revealed antigen-specific antibodies elicited by Alum- or GLA-SE- formulations. Label should be Anti-PfMSP8 (not PfsMSP-8). The authors are asked to review significant differences between primary, secondary and tertiary vaccinations in anti-PfMSP-8 following Pfs25 vaccination. The background level of antiPfMSP8 antibodies were quite high following Pfs25 vaccination. Why is this so?

All Figures. In figures 3 and 4, the authors started to show comparisons between vaccination groups. Were these comparisons also done with other figures? Please clarify statistical tests - which ones are significant and which ones are not.

The authors are requested to comment on how the outcomes of the membrane feeding assays maybe translatable to human vaccinations.

Reviewer \#2: This manuscript presents immunogenicity results in mice when Pfs25 is used in combination with rPfMSP1/8 as a step towards the development of multistage subunit malaria vaccines. In addition, in several experiments authors tested antigen doses (0.5 ug vs 2.5 ug) and two adjuvants (alhydrogel vs GLA-SE). Overall, this is an original research, methods are described in sufficient detail, the study met applicable standards, and conclusions are appropriate. Authors generated a bivalent vaccine, indeed promising and their selected formulation warrants testing in further trials. Interesting is that rPfs25/8-AHG vaccine induced high and comparable titers against Pfs25 irrespective of dose and this was comparable to rPfs25/8-GLA-SE at the highest concentration. GLA-SE influenced more on the IgG subtype. From Table 1, alum adjuvant seems to be more effective than GLA-SE adjuvant, then the preferred formulation with GLA-SE was based on combination with PfMSP1.

I am confused though about the following description in Methods, Lines 141-143: \"For antibody analysis, sera were collected three weeks following the first two immunizations and 4 weeks following the final immunization. For T cell studies, mice received a third boost administered by intraperitoneal (i.p.) injection, 8-10 weeks following the final subcutaneous immunization.\"\-- From the description, my understanding is there are 2 vaccinations of 3 week interval, then a third vaccination happened 4 weeks after second dose. For T cell studies, the third dose was administered by ip 8-10 weeks after 2nd vaccine dose? Is this understanding correct and could the authors give additional justification/comment why the third dose would be an ip boost with a different schedule than the rest?

For SMFA, in methods it states that vaccine-induced IgG were mixed at indicated concentrations; in results\-- only at one concentration= 750ug/mL. I think then it is best to state the concentration used in the methods section (if indeed only one concentration was used).

In Fig. 9, it was described that strong and similar levels of IgG1 were detected in all groups regardless of antigen formulation or adjuvant but all alum based formulations have very low levels of IgG2a/c and IgG2b\-- However, the figure does reflect low levels but not so low. In fact IgG2a/c levels from alum is comparable to that of GLA-SE; IgG2b is lower but almost comparable to IgG1. Only IgG3 was much lower compared to GLA-SE.

minor commend: Discussion: Line 519, \"male and female recipients\", best to specify male and female mice

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232355.r002
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Response to Reviewers

Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination (PONE-D-19-31841)

Thank you for the comments from the review of our manuscript. We were happy to see that the reviewers felt our studies had merit and that we have the opportunity to submit a revised manuscript that addresses the points raised during the review process. We have addressed journal requirements and the reviewers' comments as follows:

Journal Requirements.

1\. PLOS ONE'S style requirements.

We have reviewed the PLOS ONE style templates (main body, title page) including those for naming files. We have revised our manuscript throughout to meet these format requirements.

2\. Competing Interests Section.

We confirm that our stated competing interest does not alter our adherence to all PLOS ONE policies on sharing data and materials. In our cover letter, we have included an update to our competing statement by adding the following: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials."

3 and 4. Data not shown.

In our original manuscript, we had four instances of 'data not shown'. In the revised manuscript, we have added two supplemental tables (S1 and S2 Tables), updated Fig S2 to include 4 panels of additional data, and included one additional supplemental figure (Fig S4). These provided the relevant data that we originally referenced as 'not shown'. In the fourth instance, we felt that the data were not a core part of the research being presented in this study and have removed the phrase from the revised document.

Reviewer \#1.

1\. Figure 1: The authors concluded that both Pfs25 and Pfs28 domains induce antigen-specific T cell response regardless of the vaccine formulation. Whilst they appear not significant, some responses appear higher than they should be (e.g. 2.5 ug dose -- anti-PfMSP8 response in the Pfs25-vaccinated mice, anti- Pfs25 response in the PfMSP8-vaccinated mice; and in some other groups -- whilst responses in the alum or GLA-SE only groups really showed poor responses). Could the authors comment on this? What could be causing the residual responses? The authors say that graphs depict mean SI +/- SD -- how many wells/group? The anti-Pfs25 response seems to be lower in the Pfs25/8 formulation with GLA-SE than the other groups in the 2.5ug dose. Why is this so?

i\. The reviewer correctly notes that we see slightly higher than expected proliferation of cells from rPfs25-vaccinated mice when stimulated with rPfMSP8 as well as the reverse, the proliferation of cells from rPfMSP8 vaccinated mice when stimulated with rPfs25. We had commented on similar findings in our antibody data presented in Figure 3 and 4. As these responses are above that observed in adjuvant control, we expect this is due to a shared epitope(s) between rPfs25 and rPfMSP8 associated with a common His-tag leader and linker sequence. Of interest, this cross-reactive response is more prominent in Alum-based formulations versus GLA-SE-based formulations. Importantly, the level of cross-reactive response we observe in these in vitro assays is low in comparison to the potent responses directed against the homologous antigen used for immunization. We have modified both the results further to note these observations.

ii\. For the proliferation data presented in Figure 1, the stimulation indices (+/-SD) were calculated based on five mice per group, with each assay including triplicate wells per mouse and per condition. We have modified the Materials and Methods to clarify this point.

iii\. The reviewer correctly points out that we see a reduced rPfs25-specific proliferative response of cells from mice immunized with 2.5 µg of Pfs25/8 formulated with GLA-SE. We had noted this in our original manuscript and have now modified the text to suggest a possible explanation. We expect that this may be due to some shift of the T cell response toward epitopes in rPfMSP8 at the higher doses but this will require further investigation. Importantly, this potential difference in T cell epitope utilization had no impact on the magnitude or functionality of the antibody responses directed to rPfs25 in rPfs25/8 immunized mice.

2\. Figure 2. The authors showed cytokine production by CD4+ T cells following vaccination. The methodology indicated that the authors also looked at IL-2 and IL-4, but no data was provided for these cytokines.

These data were originally referenced as 'data not shown'. We now provide these data in two supplementary tables (S1 and S2 Tables) and in four panels added to S2 Fig.

3\. Figures 3 and 4. The authors revealed antigen-specific antibodies elicited by Alum- or GLA-SE- formulations. Label should be Anti-PfMSP8 (not PfsMSP-8). The authors are asked to review significant differences between primary, secondary and tertiary vaccinations in anti-PfMSP-8 following Pfs25 vaccination. The background level of antiPfMSP8 antibodies were quite high following Pfs25 vaccination. Why is this so?

The labels have been corrected to indicate 'anti-PfMSP8'. We have added information on the statistical analysis of the anti-PfMSP8 response following immunization with rPfs25, noting a significant increase in secondary or tertiary immunization. We addressed this observation in our original manuscript as follows: 'This reactivity is associated with a shared epitope(s) present within the His-tag and linker that are common to both antigens. This reactivity is relatively low, representing only 1-2% of the overall anti-Pfs25 titer induced by immunization with unfused rPfs25 (Fig 3A-B).'

4\. All Figures. In figures 3 and 4, the authors started to show comparisons between vaccination groups. Were these comparisons also done with other figures? Please clarify statistical tests - which ones are significant and which ones are not.

Our studies evaluated three main parameters (antigen, adjuvant, dose) to determine the formulation that induces optimal immune responses upon immunization. We have completed a comprehensive statistical evaluation of immune responses. For clarity of our presentation of the statistical analysis however, we tried to draw attention to comparison regarding specific scientific questions for each set of data deemed most appropriate. For example in the T cell analysis, the focus was on defining the domain-specificity (via proliferation; Fig. 1) and type (Th1 or Th2 via domain-specific cytokine production, Fig 2) of the responding T cells. Here, comparisons of immunized mice versus adjuvant controls within a group were key and were highlighted. However, for the antibody analysis, it was important for us to include some comparison of responses between groups to address the question of competition between antigens when formulated in combination (i.e. Figures 3-5, 7). As noted above, we have included additional statistical analysis in Figure 3 and 4. We have clarified aspects of the statistics in Figure 5. We have added statistical analysis of the IgG1 response in Figure 9. We would be happy to include any additional statistical analysis that reviewers or the editors feel would be meaningful and would improve the manuscript.

5\. The authors are requested to comment on how the outcomes of the membrane feeding assays maybe translatable to human vaccinations.

We have added the following comment to the Discussion.

"Furthermore, we observed potent transmission-reducing activity of vaccine-induced IgG at a concentration of 750 µg/ml, a value 1- to 3-fold lower than the normal level of IgG in mouse serum. These data increase the likelihood that immunization of human subjects with Pfs25/8 formulated with GLA-SE can induce functional antibodies that significantly impact parasite transmission if comparable vaccine immunogenicity is achieved."

Reviewer \#2.

1\. I am confused though about the following description in Methods, Lines 141-143: \"For antibody analysis, sera were collected three weeks following the first two immunizations and 4 weeks following the final immunization. For T cell studies, mice received a third boost administered by intraperitoneal (i.p.) injection, 8-10 weeks following the final subcutaneous immunization.\"\-- From the description, my understanding is there are 2 vaccinations of 3 week interval, then a third vaccination happened 4 weeks after second dose. For T cell studies, the third dose was administered by ip 8-10 weeks after 2nd vaccine dose? Is this understanding correct and could the authors give additional justification/comment why the third dose would be an ip boost with a different schedule than the rest?

We apologize for the confusion and have modified the Materials and Method to clarify the immunization protocol. For assessment of antibody responses, mice were immunized subcutaneously, three times at 4-week intervals. Sera samples were collected three weeks following the first two immunizations and 4 weeks following the final immunization. For assessment of T cell responses, mice were immunized subcutaneously three times at 4-week intervals. Following an 8-10 week rest, mice received an additional boost administered by intraperitoneal (i.p.) injection to increase trafficking of antigen-specific T cells to the spleen. Splenocytes were harvested 2 weeks following the i.p. boost.

2\. For SMFA, in methods it states that vaccine-induced IgG were mixed at indicated concentrations; in results\-- only at one concentration= 750ug/mL. I think then it is best to state the concentration used in the methods section (if indeed only one concentration was used).

We have modified the Materials and Methods to indicate that purified IgG was tested at a concentration of 750 µg/ml.

3\. In Fig. 9, it was described that strong and similar levels of IgG1 were detected in all groups regardless of antigen formulation or adjuvant but all alum based formulations have very low levels of IgG2a/c and IgG2b\-- However, the figure does reflect low levels but not so low. In fact IgG2a/c levels from alum is comparable to that of GLA-SE; IgG2b is lower but almost comparable to IgG1. Only IgG3 was much lower compared to GLA-SE.

We thank the reviewer for pointing out a discrepancy between the data presented in Figure 9 and our description of the findings in the Results section with regard to vaccine-induced IgG1 and IgG2a/c levels. We discovered an error in Figure 9. While the description of the data in the text was accurate, the panels for IgG1 and IgG2a/c in Figure 9 were switched. We have corrected this error in the Figure. We show that strong and similar levels of IgG1 were detected in all groups regardless of antigen formulation or adjuvant, we do see difference in vaccine-induced IgG2a/c with significantly higher levels in GLA-SE vs Alum based formulation. We apologize for this error and are happy to have had the opportunity to correct the mistake and this point in the review process.

4\. Minor comment: Discussion: Line 519, \"male and female recipients\", best to specify male and female mice

The sentence has been change to read 'male and female mice'.
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Dear Dr. Burns, Jr.,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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